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Objectives: To test the performance of different analytical approaches in highlighting the 
occurrence of deregulated redox status in various physio-pathological  situations. 
Design and Methods: 35 light and 61 heavy smokers, 19 chronic renal failure, 59 kidney 
transplanted patients, and 87 healthy controls were retrospectively considered for the study. 
Serum oxidative stress and antioxidant status, assessed by spectrophotometric Reactive 
Oxygen Metabolites (d-ROMs) and Total Antioxidant Capacity (TAC) tests, respectively, 
were compared with plasma free (F-MDA) and total (T-MDA) malondialdehyde, both 
quantified by isotope-dilution gas chromatography-mass spectrometry (ID-GC-MS). 
Sensitivity, specificity and cut-off points of  T-MDA, F-MDA, d-ROMs and TAC were 
evaluated by both receiver-operator characteristic (ROC) analyses and area under the ROC 
curve (AUC). 
Results: Only T-MDA assay showed clearly absence of oxidative stress in controls and 
significant increase in all patients (AUC 1.00, sensitivity and specificity 100%). Accuracy 
was good for d-ROMs (AUC 0.87, sensitivity 72.8%, specificity 100%) and F-MDA (AUC 
0.82, sensitivity 74.7%, specificity 83.9%), but not high enough for TAC to show in patients  
impaired antioxidant defence (AUC 0.66, sensitivity 52.0%, specificity 92.9%). 
Conclusions: This study reveals T-MDA as the best marker to detect oxidative stress, shows 
the ability of d-ROMs to identify modified oxidative status particularly in the presence of 
high damages, and evidences the poor TAC performance. D-ROMs and TAC assays could be 
useful for routine purposes; however, for an accurate clinical data evaluation, their 
comparison versus a “gold standard method” is required. 
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Oxidative stress plays a role in different human pathological conditions; it is caused by an 
imbalance between reactive oxidants (endogenous and exogenous) and antioxidant defense 
systems [1-5]. Measuring the body’s reaction to oxidants’ attack is clinically useful to 
disclose possible oxidative imbalances, depletion of antioxidant defenses, disease progression 
and response to medical treatment. To this purpose, different biomarkers have been proposed 
as indexes of lipid peroxidation (hydroperoxides, dienes, F2-isoprostanes, malondialdehyde) 
and/or various endogenous antioxidant compounds (e.g., thiol groups, Vit A, Vit E, 
antioxidant enzymes) [6]. Ideally these methods should be used synergistically rather than as 
homologous competitive oxidative stress biomarkers, however this is unfeasible from the 
practical point of view, so it is important to distinguish the most suitable one for the diverse 
indications.  
MDA, the most abundant lipid peroxidation end-product, arising from the attack of ROS on 
PUFAs with at least 3 double bonds, is present both in a free form (F-MDA) chemically 
active and a potentially damaging agent, and bound (B-MDA) to nucleophilic groups (SH or 
NH2) of proteins and lipoproteins, indicative of an older injury and excreted by urine [7, 8]. 
Usually MDA is determined by reaction with thiobarbituric acid as thiobarbituric acid-
reactive substances (TBARS), an assay not totally specific because other aldehydes rather 
than MDA can be quantified [1, 3, 5-7, 9]. Moreover, the standard TBARs procedure 
measures only total MDA (T-MDA), i.e. the sum of F-MDA and B-MDA, while for F-MDA 
evaluation, a proteins precipitation step is needed before the derivatization reaction. 
Nonetheless, a new assay has been developed which exhibits high specificity and sensitivity 
both for free and protein bound MDA [10].  
According to the European Food Safety Authority (EFSA), MDA could be used as an index 
of oxidative damage if appropriate techniques are available for its quantification [11]. 
The high metrological level method based on gas chromatography-mass spectrometry with 
isotope dilution (ID-GC-MS) [12] allows both the direct measurement of F- and T-MDA 
concentrations, avoiding proteins precipitation. The indirect measurement of B-MDA is 
calculated as the difference between the total and free MDA amounts. The use of 
dideuterated MDA as internal standard suppresses bias occurring during hydrolysis, 
derivatization, extraction, and ensures the accuracy of the analytical process by adequate 
calibration curves. The attempt to search for an alternative non deuterated internal standard 
seems also hopeful [13, 14]. 
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Despite this highly sensitive and specific technique is expensive, time-consuming and 
affordable by a limited number of specialized laboratories, it may be conveniently used to 
confirm the results obtained by other simpler methods, more rugged and workable in a 
clinical routine.  
Some commercial assays are available either to provide a global picture of several potentially 
harmful oxidant compounds (deriving from a large class of biological molecules after the 
radicals’ attack) or to assess the serum/plasma barrier to oxidation, as total antioxidant 
capacity (TAC) [3, 15-22]. These assays allow to measure oxidative status in a quicker and 
easier way and are suitable for routine applications in a clinical laboratory setting. 
In our previous paper on critically ill patients in intensive care units [23], the sensitivity of 
the commercial assay (d-ROMs, Reactive Oxygen Metabolites), which determines 
hydroperoxides, an acute intermediate product arising from the attack of ROS on PUFAs [24, 
25], was reported to be lower than MDA determination by ID-GC-MS [12]. The poor 
performance of dROMs test [23] was attributed to many factors such as the small number of 
patients enrolled in the study, their highly critical conditions and the complex concurrent 
pharmacological treatment. The unsatisfactory performance of d-ROMs was in agreement 
with the reports of some authors [16, 19], but in marked contrast to the findings of other 
groups, who introduced the same assay for clinical routine measurements [15, 17, 18, 20-22, 
24-27]. 
Here we present a retrospective study on light and heavy smokers (LS, HS), chronic renal 
failure patients (CRF) and kidney transplant patients (KP), in order to ascertain the suitability 
of F-MDA, B-MDA, T-MDA, d-ROMs and TAC tests in different clinical settings 
characterized by oxidative stress. Thus, results from previous clinical studies [26, 28-30], 
have been collected and statistically compared for the first time, with the  aim to search for 
the best marker and/or assay and to verify their performance in evidencing oxidative stress. 
 
Materials and Methods 
Subjects 
The subjects analyzed in this study had been previously enrolled for different research 
projects approved by the local Institutional Ethics Committee and carried out according to the 
guidelines of the Helsinki Declaration. Written informed consent was obtained from all the 
subjects fulfilling the inclusion criteria.  
Written consent was obtained from all the subjects fulfilling the inclusion criteria. 
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a) LS and HS groups. Light smokers (LS) (≤ 12 cigarettes per day for at least 2 years) and 
heavy smokers (HS) (≥ 20 cigarettes/day for at least 10 years), aged between 30-60 years, 
were recruited from a pool of volunteers (Department of Pneumology, Ospedale Niguarda; 
Clinica del Lavoro "Devoto", Ospedale Maggiore Policlinico, Milan, Italy). They were in 
good health as indicated by a general medical questionnaire and by chest X-ray, pulmonary 
function, absence of respiratory complications by spirometry, electrocardiogram and clinical 
laboratory parameters. Exclusion criteria: presence of chronic diseases, cardiovascular 
episodes within 6 months (coronary artery disease, peripheral or cerebral vascular disease), 
regular medication, hypertension (defined as systolic or diastolic blood pressure higher than 
140 or 100 mmHg, respectively), impaired renal function, body mass index (BMI <19 or >25 
kg/m
2
), hyperglycemia, mellitus diabetes. The healthy controls were all non-smokers (n 57, 
M/F 30/27, aged 42.3±11.5 yrs) [28, 30]. 
b) CRF group. Chronic renal failure patients (CRF), enrolled at the Nephrology Unit 
(Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy), were on a 
conservative dietary and drug treatment to control their clinical conditions. All the patients, in 
the 20-80 years range, were selected on the basis of a renal clearance value <20 mL/min in 
two separate instances. Exclusion criteria: acute infection or peritonitis during the two 
months before the study started, neoplasm, severe malnutrition and severe hypoalbuminemia 
(<3 g/dL), liver cirrhosis, clinically symptomatic cardiac or vascular diseases, heavy smoking 
(>20 cigarettes/day for a year before recruitment). The study included also healthy controls 
(n 30, M/F 18/12, aged 59±9) [29]. 
c) KT Group. Eligibility criteria for patients who received a kidney transplant (KT) from 
cadaver or living donors at the Nephrology Unit (Fondazione IRCCS Ca’ Granda Ospedale 
Maggiore Policlinico, Milan, Italy): at least 6 months follow-up with a stable plasma 
creatinine ≤2.5 mg/dL. The immunosuppressive treatment consisted in cyclosporine A plus 
prednisone with or without azathioprine-mycophenolate mofetil, tacrolimus plus prednisone 
with or without azathioprine-mycophenolate mofetil. Exclusion criteria: patients with a 
double organ transplant, patients who had had any type of previous cardiovascular diseases 
(cerebral ischemia, atrial fibrillation, angina) and patients with mellitus diabetes diabetes 
mellitus at the time of transplant [26]. The concentrations of all MDA forms in KT patients 
were never published before. No healthy controls were enrolled in this study. 
Samples collection 
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Peripheral venous blood samples were drawn after overnight fasting; 2 blood specimens from 
each patient were collected in light protected tubes, either with no additive for serum d-
ROMs and total antioxidant capacity (TAC) measurement or containing 
ethylenediaminethetraacetic acid (EDTA) to prevent coagulation. EDTA specimens were 
immediately centrifuged to obtain plasma samples for MDA determination. All samples were 
frozen and stored at –80 °C until biochemically measured. 
Analytical methods 
Serum reactive oxygen metabolites were measured by a spectrophotometric method using the 
d-ROMs test commercial kit on FREE analyzer (Diacron International, Grosseto, Italy), as 
previously described [17, 28]. The test evaluates the ability of in vivo formed hydroperoxides 
to generate in vitro alkoxy and peroxyl radicals in the presence of transition metals acting as 
catalyzers. When free radicals react with a correctly buffered chromogenic substance, they 
develop a coloured complex showing the higher absorbance at 505 nm. The concentration of 
the coloured complex is directly proportional to the concentration of hydroperoxides. The 
resulting d-ROMs values were obtained  in arbitrary units (U.Carr., Carratelli Units), then 
converted into mmol/L of  H2O2, as 1 CARR U is stated by the manufacturer to be equivalent 
to 0.08 mg/dL. The sensitivity of the d-ROMS test was 0.26 mM H2O2, and the method was 
linear up to 267 mmol/L. Intra- and inter-assay CV’s were 2.07 and 1.79%, respectively 
Serum TAC was measured by a spectrophotometric method using the  OXY-Adsorbent test 
commercial kit on FREE analyzer (Diacron International, Grosseto, Italy), as previously 
described [26]. The test is based on the ability of hypochlorous acid (HClO) to oxidize the 
physiologic antioxidants (uric acid, glutathione, thiol groups, vitamins, glutathione 
peroxidase, superoxide dismutase and catalase). As HClO reacts with a correctly buffered 
chromogenic substrate, it forms a coloured complex that can be measured photometrically at 
505 or 546 nm. The concentration of the coloured complex is directly proportional to the 
concentration of HClO and indirectly proportional to the antioxidant ability of the sample. 
The analytical imprecision of the test is: CV within-run  1.90%; CV between-run  2.05%. 
Plasma free and total MDA were measured following the procedures described by Cighetti et 
al. [12]. For free MDA, plasma (0.2 mL) was diluted with citric buffer (0.4 mol/L; pH 4.0), 
added to butylated hydroxytoluene (0.5 mmol/L; 5 nmol) and synthesized dideuterated MDA 
(0.25 nmol) as internal standard. Samples, derivatized with phenylhydrazine (50 mmol/L; 1 
µmol) for 30 min at room temperature, were extracted with hexane and analysed by GC-MS. 
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For total MDA, plasma (0.2 mL), added with dideuterated MDA (0.25 nmol) as internal 
standard, was hydrolyzed in 1 mol/L NaOH at 60 °C for 60 minutes, then treated as described 
for free MDA. Bound MDA fraction was calculated as the difference between total and free 
MDA. The addition of butylated hydroxytoluene to the plasma samples as antioxidant and the 
low temperature for hydrolysis and derivatization reactions avoid the formation of interfering 
compounds. Moreover, the use of dideuterated MDA added to the biological samples as 
internal standard before any pre-analytical step, together with the availability of synthesized, 
purified and crystallized MDA, allows the measurement of true free and total MDA values 
using adequately prepared calibration curves [12]. The analytical imprecision of the assay is: 
CV within-run and between-run  1.0 and 1.2% for F-MDA, 0.9 and 1.1% for T-MDA, 
respectively. The laboratory cut-off for free- and total MDA is 0.50 and 2.10 µmol/L, 
respectively, derived from the mean +2SD of 500 determinations in healthy subjects enrolled 
over 10 years in different clinical studies (data not shown).  
Statistical analyses and Methods comparison 
The performance of the assays, indicating the ability to discriminate between subjects with 
increased and those with unmodified oxidative status, was evaluated by the Receiver 
Operating Characteristic (ROC) curve analysis [31] providing the corresponding cut-off 
values with the highest accuracy (minimal false negative and false positive results). The cut-
off values of each assay were identified as those maximizing the  correlation coefficient (TP 
 TN – FP  FN) / sqrt ((TP + FN)  (TN + FP)  (TP + FP)  (TN + FN)), where TP  true 
positive, FP  false positive, TN  true negative and FN  false negative, sqrt = square root 
[32, 33]. The cut-off thresholds were then derived and the area under the ROC curve (AUC), 
sensitivity (recognizing increased oxidative stress when it is truly present, i.e. identifying true 
positive rate: TP / (TP + FN)) and specificity (recognizing the true absence of oxidative 
stress, i.e. identifying true negative rate: TN / (TN + FP)) were calculated, along with their 
95% confidence intervals (CI), estimated via bootstrap (1000 runs). The assays were 
evaluated by comparing their AUC and by reporting the statistical significance of the 
difference between the areas under different ROC curves. All analyses were performed with 
the R System [34]. The strength of association between variables, for data not normally 
distributed, was identified by the robust pairwise Spearman’s coefficient and the 
corresponding 95% Confidence Intervals (CI). Post-hoc power analysis has been performed 
using the pwr libraries [35]. The power analysis and the significance were set at 0.8 and  p 
<0.05, respectively.  
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Results 
Groups whose oxidative stress parameters were retrospectively compared in this study 
include: all the apparently healthy volunteers enrolled in the different clinical studies as 
controls (CTR) (n 87; M/F 48/39; aged 47.7 10.7 ys), light smokers (LS) (n 35; M/F 25/10; 
aged 50.0 7.0), heavy smokers (HS) (n 61; M/F 35/26; aged 51.0 10.1), chronic renal 
failure patients (CRF) (n 19; M/F 14/5; aged 60.0 16.0) and kidney transplant patients (KT) 
(n 59; M/F 34/25; aged 52.5 8.4). 
The trend for each measured parameter among the groups is presented in Figure 1. Only T-
MDA could discriminate between the absence of oxidative stress in controls and the presence 
of oxidative damage in all the four studied groups. F-MDA was the only marker not 
significantly increased in CRF patients compared to controls (only 32% of subjects had 
abnormal F-MDA), while the other two MDA forms (total and bound), d-ROMs and TAC 
were significantly altered.  
As regards LS subjects, 92% and 71% showed F- and B-MDA, respectively, above their cut-
off values, while only 34% had d-ROMs in pathologic ranges. TAC value was low for each 
group compared to controls, indicating a considerably altered oxidative status as confirmed 
by all the other assays, except 64% of KT patients who maintained a good antioxidant 
capacity. 
The excellent T- MDA assay performance was confirmed by the highest accuracy for both 
sensitivity and specificity (100%) according to ROC curve analyses cut-off (T-MDA <2.10 
µmol/L) and with the highest AUC value (  1.000), indicating complete separation between 
true positive and true negative values. Compared to the highest T-MDA accuracy (Table 1), 
F-MDA presented almost the same ability to distinguish between true positive (74.7% 
sensitivity) and true negative values (83.9% specificity), whereas B-MDA slightly deferred 
from T-MDA only for sensitivity (94.3%). The d-ROMs test recognized the true negative 
(100% specificity) much better than the true positive values (72.8% sensitivity). TAC assay 
showed the lowest sensitivity identifying only 52% of the true positive values and the lowest 
AUC indicating a small difference in distribution between true positive and true negative. 
The strength of correlations among the markers obtained by pairwise Spearman test is 
reported in Table 2. T-MDA showed a significant correlation with all the variables examined 
except with TAC. Interestingly T-MDA seems stronger related with d-ROMs than with F-
MDA. F-MDA is the only MDA form which correlates with TAC (negative weak 
correlation). dROMs and TAC do not correlate.  
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Discussion 
Several methods exists for monitoring oxidative status in physio-pathological, nutritional or 
living conditions, however the poor performance of the commercial assays and  their 
inadequacy to distinguish between healthy controls and patients is still under debate, and 
results obtained by different analytical methods are often difficult to compare [19, 35 36]. 
Nevertheless, the use of commercial kits tested in the present study is still widespread among 
clinical and research laboratories for their simplicity of use and the low cost, so an additional 
study on their performance in different clinical settings merits attention. 
In this retrospective study, we evaluated the performance of two commercial assays, d-ROMs 
and TAC, which measure “families” of parameters involved in oxidative stress, to study the 
unbalance of oxidative status and antioxidant barrier caused by smoking habit and/or various 
diseases. Their ability to provide correct diagnoses was compared with free and total MDA 
assessed by ID-GC-MS [12], a high metrological level method which measures a single and 
chemically defined parameters (the endogenously formed MDA).  Of course the results were 
not compared in term of magnitude since the measured indexes are chemically different, but 
only in terms of diagnostic potency. To do this the widely accepted ROC curve analysis [36-
38 37-39] was used instead of other statistical procedures such as Passing and Bablok-
regression or Passing and Bablok-residuals. 
Of all the measured parameters (Figure 1), only T-MDA confirmed the lack of oxidative 
stress in  healthy controls and the presence of oxidative damage in all the four studied groups 
with different severity from light smokers to CRF patients. The T-MDA excellent 
performance was confirmed by the highest accuracy for both sensitivity and specificity 
(100%) as evidenced by ROC curve analyses. Consequently, we compared all the methods 
for the assessment of oxidative status against T-MDA, considered as our reference index 
(gold standard). 
Very different information was provided by the other assays. As concerns as F-MDA, it was 
unable to show CRF groups increased oxidative status (Figure 1). However, its outcome in 
CRF group is not totally surprising as F-MDA, much lower than T-MDA (less than 10%), is 
highly reactive and may be expected to be variable and not cumulative. Thus, the biochemical 
meaning of the different MDA forms needs further speculation to explain for the significant, 
but not strong correlations, between F-MDA and both B- and T-MDA (Table 2). The 
endogenous F-MDA levels depend on the balance between MDA formation and its 
detoxification as B-MDA, cleared by kidneys in urine after its transformation from protein-
MDA adducts to simpler MDA-adducts by proteolytic enzymes [8]. Thus, increased T-MDA 
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is not only indicative of increased lipid peroxidation in all pathological conditions, but can 
also arise from reduced kidney functionality, as in chronic renal insufficiency and in dialysis 
patients [29], leading to the B-MDA values in CRF higher than other groups (Figure 1). 
Similarly, unchanged F-MDA concentration is not only indicative of the lack of lipid 
peroxidation, but also represents the MDA amount remaining after F-MDA conjugation with 
proteins and aminoacids [7, 8]. Therefore, all the three MDA forms must be considered to 
frame the true oxidative status of a sample [29]. 
Concerning the d-ROMs test accuracy, its specificity was close to T-MDA in identifying true 
negative values, while its sensitivity was weaker (Table 1). This assay was able to reveal 
increased oxidative stress in a high percentage of CRF, KT and heavy smokers, but failed to 
identify most of the true positive light smoker subjects, as instead determined by the MDA 
forms (Figure 1). Thus, the d-ROMs sensitivity could rely on the intensity of the oxygen 
radical formation. In fact, the smoking damage originated by many hazardous products 
reacting as electrophilic compounds, causes an oxidative stress condition related to long 
lasting smoking and to the number of cigarettes/day; hence, heavy smokers should have a 
higher grade of oxidative stress than light smokers. The different performance of d-ROMs 
observed in this study suggests that this test is unable to assess small hydroperoxide amounts 
in vivo formed and further in vivo transformed into F-MDA, as in LS, whereas it is suitable to 
measure intense and continuous hydroperoxides formation, as in HS, CRF and KT. 
Therefore, d-ROMs assay could be partially influenced by the prevalence of the disease 
(increased oxidative stress due to high hydroperoxide amounts well identified in pathological 
conditions) [39 40], or by the pool of endogenous antioxidants and/or diet supplementations 
or drugs, modifying the indirect measurement of the in vivo formed hydroperoxides that are 
in vitro transformed into alkoxy and peroxyl radicals by the assay procedure. This statement 
could explain the ability of the d-ROMs test to show either a modified oxidative status as 
reported by some authors [15, 18, 20-22], or the lack of its performance as reported by others 
[1, 16, 19, 23]. Notably, the d-ROMs test showed weak but significant correlations with the 
MDA forms evaluated by ID-GC-MS (Table 2), although these assays are based on totally 
different principles.  
Poor performance was observed for TAC assay showing the lowest sensitivity and AUC area 
(Table 1). Nevertheless, in all the groups except KT patients, this assay evidenced a disrupted 
serum antioxidant barrier (Figure 1), as a consequence of endogenous antioxidants 
consumption to counteract the formation and/or attack of free radicals. The preserved total 
antioxidant steady-state in KT patients, despite a pro-oxidant environment as evidenced by all 
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the other tests, suggests the presence of either a basal stronger protection than in other 
groups, or some analytical interference due to co-administered pharmacological therapies. 
Thus, the evaluation of antioxidant ability alone might not be sufficient to identify the change 
in oxidative status but needs to be accompanied by other assays [16 40]. 
Study limitations: a) Comparison between MDA levels by ID-GC-MS and those resulting 
from the HPLC-TBAs assay has not been included. b) In the clinical studies considered for 
the present retrospective analysis [26, 28, 29, 30], the evaluation of plasma Vitamin E was 
never carried out as the changing of oxidative status was detected by total and reduced 
glutathione, cysteine, homocysteine and cysteinylglycine. On the other hand, when Vitamin E 
was measured [37], in contrast to significant increase in F-MDA and reduction in GSH, no 
significant changes of both alfa- and gamma tocopherol  (the two Vit E isoforms) were 
observed in patients vs controls. 
 In conclusion, the results of this retrospective study show that T-MDA, quantified by ID-
GC-MS method, is, among the evaluated markers or assays, the best index for evidencing 
oxidative stress. Our study also confirms the ability of the d-ROMs test to show modified 
serum oxidative status particularly in the presence of high damages and evidences the poor 
sensitivity of TAC assay. These two commercial assays are easy to perform, suitable for 
screening tests and useful for routine clinical purposes. Moreover, they give the possibility of 
assessing simultaneously the balance/unbalance of oxidative status. In case of critical clinical 
conditions, a more reliable and sensitive assay should be mandatory. Validation of routine 
against the “gold standard method” could help biochemists to acquire accurate data for intra-
laboratory standardization and clinicians to evaluate data more correctly. 
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